MARAVAI LIFESCIENCES HOLDINGS, INC. Financials Maravai LifeSciences Holdings, Inc.
Equities
MRVI
US56600D1072
Biotechnology & Medical Research
|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 10.53 USD | +0.67% |
|
+15.82% | +59.31% |
Valuation
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 2,748 | 5,508 | 1,882 | 865.8 | 1,389 | - | - |
| Enterprise Value (EV) 1 | 3,103 | 5,487 | 1,778 | 815 | 1,316 | 1,261 | 1,106 |
| P/E ratio | 81.2 x | 26.9 x | 8.57 x | -7.28 x | -48.1 x | -70.9 x | -161 x |
| Yield | - | - | - | - | - | - | - |
| Capitalization / Revenue | 9.67 x | 6.89 x | 2.13 x | 3 x | 5.04 x | 4.59 x | 3.98 x |
| EV / Revenue | 10.9 x | 6.87 x | 2.01 x | 2.82 x | 4.78 x | 4.16 x | 3.16 x |
| EV / EBITDA | 18.3 x | 9.42 x | 2.79 x | 12.5 x | 20.8 x | 15.7 x | 10.7 x |
| EV / FCF | 24.5 x | 15.5 x | 3.43 x | 13.4 x | 67.5 x | 19.9 x | 13.5 x |
| FCF Yield | 4.09% | 6.45% | 29.2% | 7.44% | 1.48% | 5.03% | 7.42% |
| Price to Book | 133 x | 33.8 x | 6.7 x | 3.95 x | 2.26 x | 2.48 x | 2.35 x |
| Nbr of stocks (in thousands) | 97,966 | 131,459 | 131,540 | 132,189 | 132,831 | - | - |
| Reference price 2 | 28.05 | 41.90 | 14.31 | 6.550 | 10.46 | 10.46 | 10.46 |
| Announcement Date | 3/2/21 | 2/23/22 | 2/22/23 | 2/22/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | 284.1 | 799.2 | 883 | 288.9 | 275.5 | 302.9 | 349.5 |
| EBITDA 1 | 169.2 | 582.8 | 637.8 | 65.31 | 63.39 | 80.13 | 103.3 |
| EBIT 1 | 143.3 | 558.1 | 606 | 25.06 | 18.69 | 40 | 71.05 |
| Operating Margin | 50.42% | 69.82% | 68.63% | 8.67% | 6.79% | 13.21% | 20.33% |
| Earnings before Tax (EBT) 1 | 81.7 | 530.8 | 551.5 | 617.7 | -65.2 | -30.65 | -47.7 |
| Net income 1 | 88.97 | 182 | 220.2 | -119 | -32.3 | -13.79 | -9.1 |
| Net margin | 31.32% | 22.78% | 24.94% | -41.19% | -11.72% | -4.55% | -2.6% |
| EPS 2 | 0.3454 | 1.560 | 1.670 | -0.9000 | -0.2175 | -0.1475 | -0.0650 |
| Free Cash Flow 1 | 126.8 | 353.7 | 518.9 | 60.67 | 19.5 | 63.47 | 82 |
| FCF margin | 44.63% | 44.26% | 58.76% | 21% | 7.08% | 20.95% | 23.46% |
| FCF Conversion (EBITDA) | 74.94% | 60.69% | 81.36% | 92.9% | 30.76% | 79.21% | 79.41% |
| FCF Conversion (Net income) | 142.49% | 194.31% | 235.64% | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - |
| Announcement Date | 3/2/21 | 2/23/22 | 2/22/23 | 2/22/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 228.4 | 244.3 | 242.7 | 191.3 | 204.7 | 79.02 | 68.91 | 66.86 | 74.14 | 64.18 | 71.34 | 68.34 | 71.56 | 71.5 | 74.16 |
| EBITDA 1 | 162.7 | 187 | 188.5 | 132.5 | 129.8 | 23.8 | 9.077 | 11.9 | 20.53 | 7.795 | 17.42 | 17.29 | 20.38 | 16.23 | 19.02 |
| EBIT 1 | 157.3 | 179.6 | 180.3 | 124.4 | 121.6 | 14.95 | -0.59 | 0.959 | 9.733 | -3.86 | 7.938 | 5.718 | 8.295 | 6.665 | 9.6 |
| Operating Margin | 68.85% | 73.52% | 74.29% | 65.04% | 59.41% | 18.92% | -0.86% | 1.43% | 13.13% | -6.01% | 11.13% | 8.37% | 11.59% | 9.32% | 12.94% |
| Earnings before Tax (EBT) 1 | 144.7 | 166.8 | 175 | 113.8 | 95.88 | -4.523 | -13.36 | -20.56 | 656.2 | -22.41 | -15.69 | -15.09 | -11.43 | -16.4 | -14.96 |
| Net income 1 | 55.83 | 66.86 | 71.24 | 44.47 | 37.63 | -0.067 | -6.541 | -6.462 | -106 | -12.08 | -8.075 | -8.324 | -7.104 | -10.01 | -7.455 |
| Net margin | 24.44% | 27.37% | 29.35% | 23.25% | 18.38% | -0.08% | -9.49% | -9.66% | -142.92% | -18.82% | -11.32% | -12.18% | -9.93% | -14.01% | -10.05% |
| EPS 2 | 0.4200 | 0.5000 | 0.5300 | 0.3400 | 0.2800 | - | -0.0500 | -0.0500 | -0.8000 | -0.0900 | -0.0600 | -0.0600 | -0.0467 | -0.0750 | -0.0600 |
| Dividend per Share 2 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 2/23/22 | 5/5/22 | 8/4/22 | 11/2/22 | 2/22/23 | 5/8/23 | 8/7/23 | 11/7/23 | 2/22/24 | 5/8/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net Debt 1 | 355 | - | - | - | - | - | - |
| Net Cash position 1 | - | 20.7 | 105 | 50.8 | 73.2 | 128 | 284 |
| Leverage (Debt/EBITDA) | 2.096 x | - | - | - | - | - | - |
| Free Cash Flow 1 | 127 | 354 | 519 | 60.7 | 19.5 | 63.5 | 82 |
| ROE (net income / shareholders' equity) | 77.4% | 90.1% | 51.2% | 1.39% | -2.72% | -1.39% | 4.61% |
| ROA (Net income/ Total Assets) | 9.63% | 11.4% | 10.5% | -6.31% | -0.72% | -0.81% | -0.36% |
| Assets 1 | 924.2 | 1,594 | 2,100 | 1,885 | 4,473 | 1,708 | 2,554 |
| Book Value Per Share 2 | 0.2100 | 1.240 | 2.140 | 1.660 | 4.640 | 4.220 | 4.450 |
| Cash Flow per Share 2 | 5.260 | 1.430 | 2.100 | 0.5000 | 0.2200 | 0.6600 | 0.5400 |
| Capex 1 | 25.4 | 14.9 | 17.1 | 65.6 | 32.6 | 24.9 | 22.5 |
| Capex / Sales | 8.94% | 1.86% | 1.94% | 22.69% | 11.83% | 8.23% | 6.45% |
| Announcement Date | 3/2/21 | 2/23/22 | 2/22/23 | 2/22/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
10.46
USD
Average target price
10.42
USD
Spread / Average Target
-0.37%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +59.69% | 1.39B | |
| -27.67% | 9.87B | |
| -17.30% | 2.74B | |
| -11.15% | 2.24B | |
| -22.32% | 1.63B | |
| +23.58% | 772M | |
| -1.31% | 760M | |
| -28.57% | 516M | |
| +5.37% | 310M | |
| +12.46% | 219M |
- Stock Market
- Equities
- MRVI Stock
- Financials Maravai LifeSciences Holdings, Inc.